Healium Medical, an Israeli start-up, developed a transcatheter ultrasonic ablation procedure for the treatment of atrial fibrillation that won the competition of the ICI 2019 Innovation Award. PI Ceramic manufactures the transducers for this minimally invasive treatment procedure.
Approximately 46 million patients worldwide suffer from atrial fibrillation – the most common cardiac arrhythmia, which can lead to life-threatening complications. Healium Medical has now developed a noncontact ablation procedure for the treatment of atrial fibrillation. Transcatheter ablation works with ultrasonic waves that are generated by tiny piezo elements from PI Ceramic.
The technology from Healium Medical not only reduces the time required for treatment but it also improves the quality of the procedure thanks to its real-time monitoring. Another plus of the noncontact technology is a reduced risk of injury. All in all, the solution from the Israeli start-up solves the greatest limitations of catheter ablation technologies currently being used.
ICI 2019 Innovation Award for Noncontact Ablation Using Piezo Ultrasound
Healium Medical received the ICI 2019 Innovation Award for the new transcatheter ablation procedure for the treatment of atrial fibrillation at the first International Meeting for Innovation in Cardiovascular Interventions (ICI) in Tel Aviv, Israel. Ran Sela, CEO and co-founder of the start-up company, accepted the prize money worth 100,000 USD sponsored by the Jon DeHaan Foundation at the ICI 2019 Meeting.
The start-up, founded in 2017 and based in Yokneam, Israel, has an extensive in-house research and development laboratory, a multidisciplinary team of physicists, engineers, and physicians, as well as preclinical data confirming the feasibility of its proprietary technology.
For more information, please fill out the enquiry form attached to this page.